CAD Clinical Trials
Corticosteroids are a first-line therapy for warm autoimmune hemolytic anemia, but may be less effective in patients with cold autoimmune hemolytic anemia.
The inhibition of the complement system in cold agglutinin disease has been shown to result in impressive clinical recovery.
Because cold agglutinin disease (CAD) is a rare subset of another rare disease, very few medical researchers devote entire studies to exploring it.
We examine the lasting impact of innovative clinical trial designs for rare diseases on other clinical experiments.
When I was first diagnosed with cold agglutinin disease (CAD), my symptoms were at an all-time high.
Having an autoimmune disease such as cold agglutinin disease (CAD) means you see your hematologist often.
I have CAD and I am learning how to pay attention to the more subtle signs of the disease’s progression.
Ultragenyx CEO Dr. Emil D. Kakkis said federal regulators should focus more on biomarkers and less on clinical endpoints when it comes to drug approvals.
Abstract artist Betty Usdan-Zwickler, 83, of Boca Raton, Florida, is also a fierce advocate for fellow patients with cold agglutinin disease (CAD).
The all-volunteer CAD Foundation fights for patients with a rare anemia that has no approved therapy. Three companies are conducting clinical trials.
Given the rarity of CAD and lack of comparative trials, treatment plans are primarily based on findings from nonrandomized trials and clinical experience.
Rare Care Podcast